| Literature DB >> 34092963 |
Noshin Nawar1, Anik Paul1, Hamida Nooreen Mahmood1, Md Ismail Faisal1, Md Ismail Hosen1, Hossain Uddin Shekhar1.
Abstract
Partner and Localizer of BRCA2 or PALB2 is a typical tumor suppressor protein, that responds to DNA double stranded breaks through homologous recombination repair. Heterozygous mutations in PALB2 are known to contribute to the susceptibility of breast and ovarian cancer. However, there is no comprehensive study characterizing the structural and functional impacts of SNPs located in the PALB2 gene. Therefore, it is of interest to document a comprehensive analysis of coding and non-coding SNPs located at the PALB2 loci using in silico tools. The data for 1455 non-synonymous SNPs (nsSNPs) located in the PALB2 loci were retrieved from the dbSNP database. Comprehensive characterization of the SNPs using a combination of in silico tools such as SIFT, PROVEAN, PolyPhen, PANTHER, PhD-SNP, Pmut, MutPred 2.0 and SNAP-2, identified 28 functionally important SNPs. Among these, 16 nsSNPs were further selected for structural analysis using conservation profile and protein stability. The most deleterious nsSNPs were documented within the WD40 domain of PALB2. A general outline of the structural consequences of each variant was developed using the HOPE project data. These 16 mutant structures were further modelled using SWISS Model and three most damaging mutant models (rs78179744, rs180177123 and rs45525135) were identified. The non-coding SNPs in the 3' UTR region of the PALB2 gene were analyzed for altered miRNA target sites. The comprehensive characterization of the coding and non-coding SNPs in the PALB2 locus has provided a list of damaging SNPs with potential disease association. Further validation through genetic association study will reveal their clinical significance.Entities:
Keywords: PALB2; UTR; in silico characterization; nsSNP
Year: 2021 PMID: 34092963 PMCID: PMC8131579 DOI: 10.6026/97320630017424
Source DB: PubMed Journal: Bioinformation ISSN: 0973-2063
Figure 1Workflow of nsSNP analysis.
Figure 2A Venn diagram representation of most deleterious nsSNPs estimated by various tools. (a) Deleterious nsSNPs identification by SIFT, PolyPhen 2.0, PROVEAN and PANTHER which causes functional alterations; (b) Disease inducing nsSNPs identification by SNAP2, PhD-SNP, SNPs and GO and Pmut)
Figure 3Amino acid variations distributed into conservation scale by Consurf and protein stability change prediction by I-mutant 2.0 and MUpro.
Effect of nsSNPs on the structure and function of protein predicted by MutPred 2.0.
| SNP ID | Mutant | MutPred2.0 score | Impact and probability | P-value |
| rs78179744 | C891W | 0.786 | Gain of strand (30%) | 0.003 |
| Altered transmembrane protein (22%) | 0.003 | |||
| Altered ordered interface (25%) | 0.02 | |||
| rs116967702 | C1060Y | 0.871 | Altered ordered interface (34%) | 0.001 |
| Altered metal binding (23%) | 0.04 | |||
| rs62625280 | D927V | 0.886 | Altered transmembrane protein (42%) | 0.000005 |
| Loss of loop (29%) | 0.01 | |||
| Altered ordered surface (26%) | 0.01 | |||
| rs146444298 | D1125Y | 0.81 | Altered metal binding (55%) | 0.003 |
| Altered ordered surface (41%) | 0.0003 | |||
| rs45551636 | G998E | 0.665 | Gain of intrinsic disorder (31%) | 0.04 |
| Loss of B-factor (26%) | 0.04 | |||
| rs143808171 | G1021R | 0.8 | Gain of helix (29%) | 0.01 |
| Altered transmembrane protein (26%) | 0.001 | |||
| rs62625282 | G1121D | 0.857 | Altered metal binding (39%) | 0.009 |
| rs45478192 | L939W | 0.862 | Gain of loop (27%) | 0.03 |
| Altered transmembrane protein (22%) | 0.004 | |||
| rs62625283 | W1140G | 0.942 | Altered ordered surface (48%) | 0.0003 |
| Altered metal binding (22%) | 0.02 | |||
| rs45464500 | L947S | 0.821 | Altered stability (80%) | 0.0003 |
| Gain of intrinsic disorder (46%) | 0.03 | |||
| rs141047069 | L35P | 0.848 | Altered coiled coil (90%) | 0.0007 |
| Altered disordered interface (42%) | 0.0006 | |||
| Loss of helix (28%) | 0.02 | |||
| Loss of acetylation at K30 (26%) | 0.01 | |||
| rs45566737 | L1150R | 0.811 | Gain of strand (27%) | 0.03 |
| Altered transmembrane protein (21%) | 0.004 | |||
| rs45510998 | S417Y | 0.814 | Altered ordered interface (30%) | 0.02 |
| Altered disordered interface (30%) | 0.02 | |||
| Altered DNA binding (25%) | 0.009 | |||
| Gain of allosteric site (23%) | 0.02 | |||
| rs45550935 | I887S | 0.799 | Gain of strand (27%) | 0.02 |
| Altered stability (20%) | 0.01 | |||
| rs372931676 | Q921H | 0.717 | Altered transmembrane protein (30%) | 0.0002 |
| rs200048921 | R37S | 0.622 | Altered disordered interface (47%) | 0.004 |
| Altered DNA binding (23%) | 0.01 | |||
| rs369132015 | A968G | 0.526 | Gain of strand (26%) | 0.04 |
| rs180177123 | T911I | 0.534 | Altered transmembrane protein (33%) | 0.00006 |
| Altered ordered interface (26%) | 0.01 | |||
| rs45525135 | L947F | 0.655 | Altered stability (25%) | 0.008 |
Predicted results of noncoding SNPs in miRNA target site. MiRSite: sequence context of the miRNA site: bases complementary to the seed region are in capital letters and SNPs are highlighted in bold form; Function class: D= the derived allele disrupts a conserved miRNA site (ancestral allele with support>2); C= the derived allele creates a new miRNA site; N= the derived allele disrupts a non- conserved miRNA site (ancestral allele with support<2); Context score= negative increase= increase of SNP functionality.
| SL no. | SNP ID | Allele | miRID | miRSite | Function class | Context+score change |
| 1 | rs180748355 | G | hsa-let-7c-3p | acatTTGTACAtg | D | -0.148 |
| T | hsa-miR-4495 | acattTTTACATg | C | -0.08 | ||
| hsa-miR-548c-3p | acATTTTTAcatg | C | 0.069 | |||
| 2 | rs185410736 | A | hsa-miR-1250-3p | acacttAAAATGA | D | -0.002 |
| hsa-miR-153-5p | acacttAAAATGA | D | 0.015 | |||
| hsa-miR-595 | ACACTTAaaatga | N | -0.13 | |||
| hsa-miR-7856-5p | acaCTTAAAAtga | N | -0.001 | |||
| C | hsa-miR-3616-5p | aCACTTCAAatga | C | -0.387 | ||
| hsa-miR-4795-5p | aCACTTCAaatga | C | -0.14 | |||
| hsa-miR-573 | aCACTTCAAatga | C | -0.345 | |||
| hsa-miR-579-3p | acacttCAAATGA | C | -0.116 | |||
| has-miR-664b-3p | acacttCAAATGA | C | -0.125 | |||
| 3 | G | hsa-miR-4279 | tataaAGGAGAAt | D | -0.169 | |
| rs189962793 | A | hsa-miR-130b-5p | tataAAAGAGAat | C | -0.098 | |
| hsa-miR-4753-3p | tataAAAGAGAAt | C | -0.313 | |||
| hsa-miR-6809-3p | tataaAAGAGAA | C | -0.2 |
Structural consequences prediction of nsSNPs by Project HOPE.
| Mutant Models | Difference in size | Hydrophobicity | Charge Change | Alteration in bond formation |
| C891W | Bigger | - | - | - |
| C1060Y | Bigger | Decreased | - | - |
| D927V | Smaller | Increased | Negative to neutral | Disrupts H-bond formation with Lys at position 974; |
| Disrupts salt bridge formation with Arginine at position 975 and position 976 | ||||
| D1125Y | Bigger | Increased | Negative to neutral | Disrupts salt bridge formation with lysine at position 1062 and position 1124 |
| G998E | Bigger | Decreased | Neutral to negative | - |
| G1021R | Bigger | Decreased | Neutral to positive | Disrupts local structure backbone |
| G1121D | Bigger | Decreased | Neutral to negative | - |
| L939W | Bigger | - | - | - |
| W1140G and A968G | Smaller | Decreased | - | W1140G disrupts hydrogen bond formation with Cysteine at position 1109 |
| L947F and Q921H | Bigger | - | - | - |
| L1150R | Bigger | Decreased | Neutral to positive | - |
| L947s and I887S | Smaller | Decreased | - | - |
| T911I | Bigger | Increased | - | Loss of H-bond; |
| Disrupts correct folding |
Figure 4A) Visualization of cluster formation by 4 mutant models. B) Visual representation of different amino acid interactions where (i) represents Cysteine at position 891, (ii) substituted by Tryptophan at position 891. (iii) Represents Threonine at position 911, (iv) substituted by Isoleucine at position 911. (v) Represents Leucine at position 947, (vi) substituted by Phenylalanine at position 947. C) A visual representation of structural differences in residue between wild type and mutated structure. Here, (i) Represents Cysteine at wild type structure substituted by Tryptophan at position 891. (ii) Represents Threonine at wild type structure substituted by Isoleucine at position 911. (iii) Represents Leucine at wild type structure substituted by Phenylalanine at position 947.
Figure 5A) Gene expression of PALB2 in specific tissues. B) Comparison of BRCA2 and PALB2 mutation frequency. C) Comparison of mutation frequency with PALB2 mutation carriers and without PALB2 mutation carriers.